Author: Ravi Shankar

Acquisition Expands Climb’s European Platform and Deepens Strategic Vendor Relationships

Transaction Expected to be Accretive to Earnings and Adjusted EBITDA

EATONTOWN, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) — Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb” or the “Company”), a value-added global IT channel company providing unique sales and distribution solutions for innovative technology vendors, has completed the acquisition of NeoVAD, a France-based value-added IT distributor focused on cybersecurity, cloud services and virtualization, serving reseller partners across the French market, for an aggregate purchase price of approximately €16.0 million ($18.0 million¹).

NeoVAD brings its established presence in France to Climb with approximately 300 active resellers and vendor relationships including Cato Networks, DataCore and Netwrix, among others. For its fiscal year ended December 31, 2025, NeoVAD generated EBITDA of approximately €2.2 million² ($2.5 million)³, which was up 487% from approximately €378,000² ($427,000)³ the prior fiscal year.

Management Commentary

“NeoVAD is a strong fit with our strategy to continue expanding Climb’s scale and capabilities across Europe,” said Climb CEO Dale Foster. “The acquisition adds meaningful reach in France while strengthening several important vendor relationships and creating opportunities to bring more of Climb’s portfolio to NeoVAD’s reseller network. At the same time, NeoVAD’s established position in France can help us build greater depth with vendors including Cato Networks, DataCore and Netwrix across our broader platform. We also see a meaningful opportunity to expand our Microsoft distribution business by pairing our existing EMEA capabilities with NeoVAD’s local training and technical support expertise. We expect this acquisition to be accretive to earnings and adjusted EBITDA, while NeoVAD’s stronger margin profile further supports our profitability objectives and expands our European platform for continued growth.”

Commenting on the acquisition, NeoVAD Founder and CEO Jérôme Boulon stated: “For more than a decade, we have built NeoVAD around a focused portfolio of cybersecurity, cloud and virtualization solutions and a high-touch model designed to help resellers successfully bring those technologies to market. Climb shares our focus on specialized, value-added distribution and brings broader scale and capabilities that can help us build on what we have established in France. We see significant opportunity to expand the solutions we bring to our reseller partners while creating additional opportunities for our vendors across Climb’s European platform.”

Additional information can be found in Climb’s Current Report on Form 8-K to be filed with the Securities and Exchange Commission on October 22, 2026.

About Climb Global Solutions

Climb Global Solutions, Inc. (NASDAQ:CLMB) is a value-added global IT distribution and solutions company specializing in emerging and innovative technologies. Climb operates across the U.S., Canada and Europe through multiple business units, including Climb Channel Solutions, Grey Matter and Climb Global Services. The Company provides IT distribution and solutions for companies in the Security, Data Management, Connectivity, Storage & HCI, Virtualization & Cloud, and Software & ALM industries.

Additional information can be found by visiting www.climbglobalsolutions.com.

About NeoVAD

NeoVAD is a value-added IT distributor headquartered in Boulogne-Billancourt, France, serving reseller partners across the French market. The company specializes in cybersecurity, cloud services and virtualization solutions and maintains relationships with technology vendors including Cato Networks, DataCore and Netwrix, among others. NeoVAD operates a fully indirect, two-tier distribution model supporting approximately 300 active resellers, integrators and MSPs. Through its high-touch approach, the company provides presales, technical training, marketing and demand-generation support designed to help partners successfully bring vendor solutions to market.

Non-GAAP Financial Measures

Climb uses non-GAAP financial measures, including adjusted EBITDA, as supplemental measures of the performance of the Company’s business. Use of these financial measures has limitations, and you should not consider them in isolation or use them as substitutes for analysis of Climb’s financial results under generally accepted accounting principles in the United States of America (“U.S. GAAP”).

Forward-Looking Statements

The statements in this release, other than statements of historical fact, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are intended to come within the safe harbor protection provided by those sections. These forward-looking statements are subject to certain risks and uncertainties. Many of the forward-looking statements may be identified by words such as ”looking ahead,” “believes,” “expects,” “intends,” “anticipates,” “plans,” “estimates,” “projects,” “forecasts,” “should,” “could,” “would,” “will,” “confident,” “may,” “can,” “potential,” “possible,” “proposed,” “in process,” “under construction,” “in development,” “opportunity,” “target,” “outlook,” “maintain,” “continue,” “goal,” “aim,” “commit,” or similar expressions, or when we discuss our priorities, strategy, goals, vision, mission, opportunities, projections, intentions or expectations. In this press release, the forward-looking statements relate to, among other things, declaring and reaffirming our strategic goals, future operating results, and the effects and potential benefits of strategic acquisitions on our business. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include, without limitation, our ability to recognize the anticipated benefits of the acquisitions of NeoVAD and interworks.cloud, the possibility that the anticipated earnings and adjusted EBITDA accretion, synergies, margin improvements and other strategic benefits of the NeoVAD acquisition may not be realized within the expected timeframe or at all; difficulties integrating NeoVAD’s operations, employees, systems and distribution activities; the Company’s ability to retain key NeoVAD personnel, resellers and vendor relationships; and changes in the commercial terms, availability or performance of material vendor arrangements; the continued acceptance of the Company’s distribution channel by vendors and customers, the timely availability and acceptance of new products, product mix, market conditions, competitive pricing pressures, the successful integration of acquisitions, contribution of key vendor relationships and support programs, inflation, import and export tariffs, the successful integration artificial intelligence tools, interest rate risk and impact thereof, as well as factors that affect the software industry in general. The forward looking statements contained herein are also subject generally to other risks and uncertainties that are described in the section entitled “Risk Factors” contained in Item 1A. of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and from time to time in the Company’s filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of this release, except as required by law.

Company Contact

Matthew Sullivan
Chief Financial Officer
(732) 847-2451
MatthewS@ClimbCS.com

Investor Relations Contact

Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
CLMB@elevate-ir.com

---

¹ Amount converted from EUR to USD based on an exchange rate of €1 = $1.12 as of 10/21/26.
² Amount derived from the internal financial statements prepared by management of NeoVAD and may not be comparable to Climb’s non-GAAP measures.
³ Amount converted from EUR to USD based on average exchange rate during the 12-month period ended December 2025 (€1 = $1.13).

SCOTTSDALE, Ariz., Oct. 22, 2026 (GLOBE NEWSWIRE) — WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary flexible space solutions, today announced that it will release its third quarter 2026 financial results on November 5, 2026, after market close.

The Company’s management team will host a conference call and webcast on November 5, 2026, at 5:30 p.m. EST to discuss the Company’s results.

To access the live call by phone, use the following link by clicking here to obtain registration details.

You will be provided with dial-in details after registering. To avoid delays, we recommend that participants dial into the conference call 15 minutes ahead of the scheduled start time. A live webcast will also be accessible via the “Events & Presentations” section of the Company’s website www.investors.willscot.com. An archived version of the webcast will be available for 12 months following the call.

The Company also announced today that it will participate in the following investor conferences:

• Baird Global Industrial Conference
  Date: November 10-11, 2026
  Location: Chicago, Illinois

• Bank of America Leveraged Finance Conference
  Date: December 1, 2026
  Location: Boca Raton, Florida

• UBS Global Industrials and Transportation Conference
  Date: December 2, 2026
  Location: Manalapan, Florida

• Oppenheimer Winter Industrial Summit
  Date: December 8-9, 2026
  Location: Virtual

Portfolio managers and analysts who wish to request an in-person meeting should contact their sales representative at the sponsoring firm. Please check the “Events & Presentations” section at www.investors.willscot.com for updated details, including timing and links for potential webcasting.

About WillScot

WillScot (Nasdaq: WSC) is a leading provider of innovative turnkey space solutions in North America, helping customers keep projects moving and operations running. The Company partners with critical industries including construction, manufacturing, healthcare, government, energy and education to deliver the right solutions coupled with a high level of customer service. WillScot’s comprehensive portfolio of products – including modular complexes, dry and cold storage containers, blast-resistant buildings, clearspan industrial structures, fencing, and add-on furnishings and equipment – is customizable and flexible to support any project need. Headquartered in Scottsdale, Ariz., WillScot operates from a network of approximately 240 branch locations in the U.S., Canada, and Mexico.

Additional information can be found on the company’s website at www.willscot.com.

Contact Information

Investor inquiries:
Charlie Wohlhuter
Investors@willscot.com

Media inquiries:
Juliana Welling
Media@willscot.com 

Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable Tolerability

MIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapies for neurologic, inflammatory and metabolic disorders, today announced positive results from a 21-day preclinical proof-of-concept study evaluating oral MIRA-55 in a validated model of chronic inflammatory pain. The results support the continued advancement of MIRA-55 toward an Investigational New Drug (IND) submission.

The study demonstrated that once-daily oral MIRA-55 significantly reduced both mechanical and thermal pain hypersensitivity (p < 0.001 versus vehicle) as from the lowest dose used. MIRA-55 achieved pain-relieving effects comparable in magnitude to celecoxib (Celebrex®), a widely prescribed medication for pain and inflammation, at the higher doses evaluated.

Importantly, the effects were maintained throughout the three-week study without evidence of tolerance. MIRA-55 also reduced inflammation-associated swelling and was well tolerated, with no adverse clinical signs observed during repeated daily administration.

These findings build on MIRA’s earlier preclinical studies, including previously reported results demonstrating that oral MIRA-55 normalized pain responses and reduced inflammation in an acute inflammatory pain model, outperforming injected morphine in that study. Together, these findings extend MIRA-55’s demonstrated preclinical analgesic activity into a model of persistent, chronic inflammatory pain, further supporting its development as a next-generation oral therapy designed to provide effective, long-term pain relief with an improved safety and tolerability profile.

Key Study Highlights

• Significant Pain Relief: MIRA-55 significantly reduced both mechanical and thermal pain hypersensitivity compared with vehicle-treated animals (p < 0.001).
• Comparable to Celebrex: MIRA-55 demonstrated pain-relieving effects comparable in magnitude to celecoxib, with no statistically significant differences observed between those treatments.
• Sustained Efficacy Without Observed Tolerance: Pain relief was maintained throughout the three-week study, with no observed decline in effectiveness during repeated daily dosing.
• Reduced Inflammation-Associated Swelling: MIRA-55 reduced paw swelling to a similar magnitude as the reduction observed with celecoxib.
• Consistent Results Across Both Sexes: MIRA-55 demonstrated comparable pain-relieving activity in male and female animals.
• Favorable Observed Tolerability: No adverse clinical signs or deaths were reported, and normal body-weight gain was maintained throughout the treatment period.

Advancing a Potential New Treatment for Chronic Inflammatory Pain
Chronic inflammatory pain remains a significant medical challenge, affecting patients with conditions such as arthritis and other inflammatory disorders. Existing treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs), can provide meaningful relief but may be limited by gastrointestinal, cardiovascular, renal, and other safety considerations, particularly with prolonged use.

MIRA-55 is a next-generation oral synthetic cannabinoid analog designed to modulate cannabinoid receptor pathways involved in pain signaling and inflammation. The program aims to deliver effective, sustained pain relief while minimizing unwanted effects associated with existing treatment approaches.

The U.S. Drug Enforcement Administration has determined that MIRA-55 is not a controlled substance.

“We are building a differentiated pain therapeutics franchise around two distinct programs addressing major unmet medical needs,” said Erez Aminov, Chairman and Chief Executive Officer of MIRA Pharmaceuticals. “With Ketamir-2 advancing toward Phase 2 clinical development for neuropathic pain and MIRA-55 progressing toward an IND for inflammatory pain, we are creating a pipeline of oral therapies targeting distinct but complementary areas of pain. We believe this strategy positions MIRA to create meaningful value for patients and shareholders as both programs advance through development.”

Study Design and Scientific Findings
The 21-day study was conducted by an independent contract research organization using the Complete Freund’s Adjuvant (CFA) model, a well-established preclinical model used to investigate persistent inflammatory pain.

The study included 72 male and female rats. MIRA-55 was administered orally once daily at multiple dose levels and evaluated against a vehicle control and celecoxib, an established prescription anti-inflammatory medication.

Researchers assessed mechanical and thermal pain sensitivity, inflammation-associated paw swelling, and general tolerability throughout the study.

MIRA-55 demonstrated statistically significant pain-relieving activity across all tested doses, with a dose-related response. Analgesic activity was observed following the first administration at the highest dose, while sustained effects were established within the first several days of treatment and maintained through the end of the study.

“One of the most encouraging aspects of these findings is the durability of the response,” said Itzchak Angel, Ph.D., Chief Scientific Advisor of MIRA Pharmaceuticals. “MIRA-55 demonstrated sustained analgesic activity over repeated low oral daily dosing, without evidence of tolerance, and produced consistent effects in both male and female animals. These results extend our earlier acute pain findings into a model of persistent inflammatory pain. The relationship between pain relief and reduced swelling also suggests potentially distinct contributions from pain-signaling and inflammatory pathways, which we are continuing to investigate.”

Supporting Advancement Toward Clinical Development
The positive findings provide additional proof-of-concept evidence supporting MIRA-55’s ongoing IND-enabling development program.

Additional tissue analyses are underway to evaluate inflammatory cytokines and molecular markers associated with pain signaling and neuroinflammation, including changes in the dorsal root ganglia and spinal cord. These analyses are expected to provide further insight into MIRA-55’s mechanism of action and help inform its continued development.

MIRA is advancing MIRA-55 toward a planned IND submission in the first quarter of 2027, subject to completion of the remaining required preclinical and regulatory activities.

About MIRA-55
MIRA-55 is an orally administered, next-generation synthetic cannabinoid analog being developed as a potential treatment for inflammatory pain. The compound is designed to modulate cannabinoid receptor pathways involved in pain and inflammation while minimizing unwanted psychoactive effects.

Previous preclinical studies have demonstrated analgesic and anti-inflammatory activity, including pain normalization in comparison with morphine in an acute inflammatory pain model. More recent findings demonstrate sustained pain-relieving activity in a model of chronic inflammatory pain.

The U.S. Drug Enforcement Administration has determined that MIRA-55 is not a controlled substance. MIRA-55 remains in preclinical development, and its safety and efficacy in humans have not been established.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization prospects, market opportunity, and future development of MIRA-55, SKNY-1, Ketamir-2, and the Company’s other product candidates.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Investors are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors section of the Company’s website at www.mirapharmaceuticals.com. Forward-looking statements should be considered in light of these risks and uncertainties.

Investor and Media Contact
Krystina Quintana
MIRA Pharmaceuticals
info@mirapharma.com 
(786) 432-9792

WEKA’s AI data storage and memory capabilities will support Smartbird’s dedicated AI clusters as part of a broader strategy to build a network of leading technology partners

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — Smartbird, Inc. (NASDAQ: BIRD), the enterprise AI infrastructure company, and WEKA, the AI data and memory infrastructure company, today announced a partnership to deliver managed AI infrastructure services for enterprise AI workloads. By combining WEKA NeuralMesh software with Smartbird’s dedicated AI clusters, the offering gives enterprises a fully managed AI infrastructure foundation that is sovereign by design and ready for production workloads from day one.

The agreement marks the first in a broader network of infrastructure ecosystem partnerships that will support Smartbird’s strategy to deliver a proven stack of best-of-breed technologies as a fully-managed, enterprise-grade AI infrastructure service.

Why It Matters Now: Production AI Demands Infrastructure Enterprises Can Control

As AI moves to production scale and adopts agentic AI applications that operate continuously, infrastructure economics become increasingly important: GPU utilization, power consumption, and cost per token can determine whether AI initiatives scale or stall.

At the same time, many organizations, particularly in highly regulated industries such as government, healthcare, and financial services, cannot move sensitive data into shared public cloud environments. Some also lack in-house teams with the specialized expertise to build and operate advanced AI infrastructure. Smartbird is focused on serving these organizations, offering dedicated, sovereign, private AI infrastructure delivered and operated as a managed service.

“Enterprises don’t want to assemble AI infrastructure from individual parts. They want a complete solution that works, operated by people who have done this before,” said Dr. Nadia Carlsten, president and CEO of Smartbird. “Every Smartbird AI cluster is designed around the customer’s specific requirements, whether they’re a bank, a hospital, a manufacturer, or a government agency. By incorporating WEKA NeuralMesh, Smartbird gives customers a data and memory layer proven to perform at scale. This partnership reflects our approach to building infrastructure: experienced partners, trusted technologies, and disciplined execution.”

Workload-First, Customer-First: Dedicated AI Infrastructure

Launched in June 2026, Smartbird designs, builds, and operates dedicated AI clusters for enterprises. Each cluster is delivered as a managed service, designed for the customer’s specific workloads and deployed either on-premises or in a dedicated colocation environment.

A Proven Technology Stack

Smartbird clusters incorporating WEKA NeuralMesh software deliver:

• High-performance data and memory infrastructure. Customers can deploy rapidly and ensure GPUs are continuously supplied with data, with throughput reaching hundreds of gigabytes per second.
• Fully managed, end-to-end. Smartbird delivers and operates the complete infrastructure stack: facilities, compute, networking, data infrastructure, and data orchestration. Customers get one accountable partner without having to integrate multiple vendors or manage multiple hardware release cycles.
• Sovereign by design. Customer data stays within a customer-controlled environment and runs on fully dedicated infrastructure, providing the isolation, encryption, and auditability that regulated industries require.
• A fast, efficient foundation for inference and agentic AI. As enterprise AI shifts from periodic training to persistent inference and agentic applications, the Smartbird-WEKA solution expands GPU memory capacity, shortens time to first token, and reduces recomputation, thereby lowering token costs.

“Agentic AI is unforgiving: idle GPUs and stalled pipelines land straight on the P&L statement. Enterprises have been told the fix is a tradeoff, performance or sovereignty, but that was always a failure of infrastructure, not a law of physics,” said Liran Zvibel, co-founder and CEO at WEKA. “WEKA NeuralMesh ends the tradeoff. Smartbird delivers it as dedicated clusters customers don’t have to build or operate. Together, we’re giving regulated industries production AI that runs at full speed, on infrastructure only they touch, with more output per GPU, per watt and per dollar.”

Enterprises interested in building with Smartbird can visit www.smartbird.ai. To learn more about WEKA’s AI data storage and memory solutions, visit www.weka.io/product/neuralmesh/.

About Smartbird
Smartbird, Inc. (NASDAQ: BIRD) designs, builds, and operates dedicated AI infrastructure for enterprises. Delivered as a managed service, Smartbird provides the performance, control, and security of dedicated infrastructure without requiring customers to shoulder the capital investment and operational complexity of running it themselves. Each Smartbird cluster is mapped 1:1 to its customer and deployed on-premises or in a dedicated colocation environment, with data center sites under development in the U.S. and Europe. Smartbird is headquartered in Palo Alto. Learn more at smartbird.ai.

About WEKA
WEKA is the AI data and memory infrastructure company transforming the economics of agentic AI. The WEKA® NeuralMesh™ platform unifies high-performance data storage with extended GPU memory, giving enterprises, AI cloud providers, and AI builders a single foundation for training, inference, and agentic workloads. With Augmented Memory Grid, NeuralMesh extends GPU memory capacity by 1000x, accelerates time to first token by up to 20x, and delivers 10x more concurrent users from the same GPU footprint, proven in production benchmarks. Trusted by 30% of the Fortune 50, WEKA enables organizations to scale AI faster, optimize GPU utilization, and reduce the cost of every token served. Learn more at www.weka.io or connect with us on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Smartbird’s strategy, anticipated partnerships, expected data center availability and cluster deployments, capital resources and market opportunity. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including the risks described in Smartbird’s filings with the U.S. Securities and Exchange Commission. Smartbird undertakes no obligation to update these forward-looking statements except as
required by law.

Media & IR Contacts

For Smartbird
Smartbird Investor Relations: ir@smartbird.ai
Smartbird Media Relations: press@smartbird.ai

For WEKA
WEKA Communications: pr@weka.io

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e2e0b632-0bff-4250-b6c0-2adbd47926cc

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (“GoldHaven” or the “Company”) (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) is pleased to provide an update on its ongoing diamond drilling program at the D Zone silver-lead-zinc target, located within its flagship Magno Project in northwestern British Columbia.

Highlights

• Four of five completed drill holes intersected semi-massive to massive sulphide mineralization at Middle D.
• GOH26-10 and GOH26-13 intersected approximately 10.75 metres and 13 metres, respectively, of cumulative sulphide mineralization across separate intervals.
• GOH26-10 encountered multiple mineralized horizons containing visible galena and sphalerite, together with arsenopyrite-rich sulphides and garnet-bearing skarn, highlighting the polymetallic character of the target.
• Preliminary portable XRF screening of selected drill-core locations in GOH26-10 returned individual spot readings of up to 411,000 ppm zinc (41.1% Zn), 38,500 ppm lead (3.85% Pb) and 17,600 ppm tin (1.76% Sn), with laboratory assays pending.*

*Portable XRF readings are preliminary, non-representative spot measurements and should not be interpreted as laboratory assays or indicative of interval grades.

GoldHaven has completed five diamond drill holes from two drill pads approximately 75 metres (m) apart within the Middle D area of the historically named D Zone, with four of the five completed holes intersecting semi-massive to massive sulphide mineralization within a geophysical anomaly identified in an airborne survey conducted by the Company in early 2026.

The Company is currently advancing drill hole GOH26-14 as it continues to evaluate the distribution and geometry of mineralization within the target area.

D Zone Drilling Results

The current drilling campaign is focused on evaluating the Middle D portion of the D Zone, an area of historically documented silver-lead-zinc mineralization within the Magno Project.

Rob Birmingham, President and CEO of GoldHaven, commented:

“We are encouraged by the results at D Zone, with four of our first five drill holes intersecting significant intervals of semi-massive to massive sulphide mineralization. The identification of multiple mineralized horizons, including visible lead-zinc sulphides and indications of tin-bearing skarn, is particularly interesting.

“These early results are helping us build a better understanding of the system and guide our next exploration targets. With drilling continuing and assays pending, we look forward to evaluating the potential of D Zone alongside our ongoing tungsten exploration at Kuhn.”

Table 1: D Zone Drilling Summary

DRILL HOLE ID	SULPHIDE MINERALIZATION INTERVAL APPROXIMATE LENGTH (m)	DEPTH (m)
GOH26-09	not-encountered	not applicable
GOH26-10	10.75 m	58.8-62.15 m; 91.9-98.0 m; 134.2-135.5 m
GOH26-11	0.1 m	62 m
GOH26-12	1.0 m	68-69 m
GOH26-13	13.0 m	13-17 m; 20-29 m
GOH26-14	in progress	–

Reported intervals represent visual geological observations along drill core and are not necessarily true widths. Assay results are pending. The presence of sulphides does not necessarily indicate economically significant grades of silver, lead, zinc or other metals.

Figure 1: Middle D Zone 2026 drill locations and sulphide intersections. Intervals represent downhole lengths, not true widths. Assays pending.

Detailed Geological Observations – GOH26-10

GOH26-10 intersected four distinct mineralized zones between approximately 58.8 and 138.1 metres downhole, including 10.75 metres of cumulative semi-massive to massive sulphide mineralization and an additional 0.7 metres of mineralized skarn across separate intervals.

The upper zone (58.8–62.15 m) contains visible galena and sphalerite associated with pyrite and pyrrhotite. Deeper intervals (91.9–98.0 m and 134.2–135.5 m) contain predominantly pyrite, pyrrhotite and arsenopyrite, with locally observed sphalerite, reported cassiterite and hematite alteration. A fourth interval (137.4–138.1 m) comprises garnet-bearing, hematite-altered skarn.

These contrasting mineral assemblages may reflect different mineralization conditions within the D Zone system and will help guide ongoing geological interpretation and exploration targeting.

Figure 2: Drill core from GOH26-13 showing visually prominent metallic sulphide mineralization within the Middle D Zone at GoldHaven’s Magno Project.

Figure 3: Drill core from GOH26-10 showing sulphide mineralization within the upper polymetallic replacement-style zone, where geological logging identified galena and sphalerite associated with pyrite and pyrrhotite.

Preliminary Portable XRF Observations

Portable X-ray fluorescence (pXRF) screening of selected drill core using a SciAps X-505 handheld analyzer returned individual spot readings of up to 411,000 ppm zinc (41.1% Zn) at 134.6 metres, 280,500 ppm zinc (28.05% Zn) and 38,500 ppm lead (3.85% Pb) at 61 metres, and 17,600 ppm tin (1.76% Sn) at 93.6 metres in GOH26-10.

These preliminary measurements were obtained from select locations on heterogeneous mineralized core for geological screening purposes. They are subject to analytical limitations, including potential matrix effects, and are not laboratory assays or representative of grades across the reported drill intervals. Laboratory assays are pending and may differ materially from the pXRF readings.

The SciAps X-505 handheld pXRF analyzer is calibrated before each use using the manufacturer-provided calibration plate. Geochemical reference standards used in the drill program’s QA/QC procedures are also analyzed regularly with the pXRF to monitor instrument performance.

Historical Mineralization and Exploration Potential

The D Zone has been the subject of historical exploration, including drilling that reportedly intersected significant silver-lead-zinc mineralization.

Historical results include a reported interval of 7.6 metres grading 240 g/t silver, 4.73% lead and 4.74% zinc, providing context for the mineralization historically encountered in the broader D Zone area.

Historical results are from 1982 exploration drilling and have not been independently verified by the Company. They are provided for historical context and are not necessarily indicative of current drilling results.

GoldHaven’s 2025 surface exploration program also identified high-grade polymetallic mineralization across portions of the Magno Project.

The Company is investigating whether the sulphide mineralization encountered in the current drilling is associated with the historically documented mineralized system and how the mineralized intervals relate to one another. The Middle D area is located in a geophysical anomaly identified in the airborne survey conducted in early 2026.

Historical drill results and surface samples are not necessarily representative of grades or widths in the current drill holes.

Next Steps

GoldHaven’s near-term priorities at D Zone include:

1. Completing GOH26-14 and evaluating additional drill targets within the Middle D area.
2. Completing geological logging, sampling and submission of mineralized drill core for laboratory analysis.
3. Integrating drill-hole information into updated geological plans and cross-sections to evaluate the potential continuity and orientation of mineralization.
4. Reviewing the current drill results in the context of historical drilling and 2025 surface sampling.
5. Reporting assay results as they become available and have undergone appropriate quality assurance and quality control review.

The Company will provide further updates as exploration progresses.

Qualified Person:

The technical and scientific information contained in this news release has been reviewed and approved by Raymond Wladichuk, P.Geo., who is a non-independent Qualified Person as defined under NI 43-101 and a consultant of the Company.

About GoldHaven Resources Corp.

GoldHaven Resources Corp. is a Canadian junior exploration company focused on advancing highly prospective mineral projects in North and South America. The Company’s flagship asset is the district-scale Magno Project in the Cassiar District of northern British Columbia. GoldHaven also owns the Three Guardsmen copper-gold project in British Columbia and the Copeçal Gold Project in Mato Grosso, Brazil. In addition, the Company holds a portfolio of critical mineral projects in Brazil.

On Behalf of the Board of Directors

Rob Birmingham, Chief Executive Officer

For further information, please contact:
Rob Birmingham, CEO
www.GoldHavenresources.com
info@goldhavenresources.com
Office Direct: (604) 629-8254

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE- Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward-Looking Information

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, those listed below under the heading “Forward-Looking Statements in This News Release” are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “will”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “potential”, “scheduled”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that there will be investor interest in future financings, market fundamentals will result in sustained precious and base metals demand and prices, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future exploration and development of any future projects in a timely manner, the availability of financing on suitable terms for exploration and development of future projects and the Company’s ability to comply with environmental, health and safety laws, that exploration activities at the D Zone, including the completion of drill hole GOH26-14, geological logging, sampling and the submission of drill core for laboratory analysis, will proceed as planned and without material delay, that laboratory assay results will be received in a timely manner, that the Company’s geological interpretations of visual observations and pXRF readings are reasonable, and that weather, site access and the availability of drilling equipment, contractors and personnel will not adversely affect the program.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including, operating and technical difficulties in connection with mineral exploration and development activities, actual results of exploration activities, including the risk that laboratory assay results may not confirm visual observations or pXRF readings or may not indicate economically significant grades, the risk that historical results cannot be verified or are not representative of current drilling, changes in geological interpretation, adverse weather and seasonal access conditions in northern British Columbia, the availability of drilling equipment, contractors and personnel, the estimation or realization of mineral reserves and mineral resources, the inability of the Company to obtain the necessary financing required to conduct its business and affairs, as currently contemplated, the timing and amount of estimated future production, the costs of production, capital expenditures, the costs and timing of the development of new deposits, requirements for additional capital, future prices of precious and base metals, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, lack of investor interest in future financings, accidents, labour disputes and other risks of the mining industry, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, changes in laws, regulations and policies affecting mining operations, title disputes, the inability of the Company to obtain any necessary permits, consents, approvals or authorizations, including by the Exchange, the timing and possible outcome of any pending litigation, environmental issues and liabilities, and risks related to joint venture operations, and other risks and uncertainties disclosed in the Company’s latest interim Management’s Discussion and Analysis filed with certain securities commissions in Canada. All of the Company’s Canadian public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this news release or incorporated by reference herein, except as otherwise required by law.

Forward-Looking Statements in This News Release

The following statements in this news release constitute forward-looking information:

• statements regarding the Company’s ongoing diamond drilling program at the D Zone, including the completion of drill hole GOH26-14 and the evaluation of additional drill targets within the Middle D area;
• the anticipated completion of geological logging, sampling and the submission of mineralized drill core for laboratory analysis, and the timing of receipt and reporting of assay results following appropriate quality assurance and quality control review;
• statements regarding the potential for laboratory assay results to differ from preliminary pXRF readings and visual observations;
• the interpretation that contrasting mineral assemblages may reflect different mineralization conditions within the D Zone system, and the expectation that such observations will help guide ongoing geological interpretation and exploration targeting;
• the Company’s investigation of whether the sulphide mineralization encountered in current drilling is associated with the historically documented mineralized system, and how the mineralized intervals relate to one another;
• the integration of drill-hole information into updated geological plans and cross-sections to evaluate the potential continuity and orientation of mineralization, and the review of current drill results in the context of historical drilling and 2025 surface sampling;
• statements regarding the potential of the D Zone, the polymetallic character of the target and the Company’s ongoing tungsten exploration at Kuhn; and
• the Company’s intention to provide further updates as exploration progresses.

Infographics accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/c08b8c09-ac4b-4082-a218-c2f923a3fc8c

https://www.globenewswire.com/NewsRoom/AttachmentNg/f3241633-3251-4765-abb4-3ffb3f8e2693

https://www.globenewswire.com/NewsRoom/AttachmentNg/2d71132e-f55b-425a-b4e4-acc793cdd7b6

Deep Isolation-sponsored event will bring together leaders in nuclear energy, finance and civil society to explore responsible power growth

PLANO, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) — Deep Isolation Nuclear, Inc. (OTCQB: DBHL) (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced that President and Chief Executive Officer Rod Baltzer will participate in The energy horizon: responsible power growth, an Economist Enterprise event scheduled for Nov. 9 at the Yale Club in New York City. The event will bring together leaders from the energy, finance and civil society sectors to explore how nuclear power can help meet rising electricity demand.

Baltzer will be joined by Shawn Reynolds, portfolio manager at VanEck, and Laura Hermann, deputy executive director of Energy Communities Alliance. The discussion will examine the opportunities and responsibilities associated with expanding nuclear energy, including the role of financing, public confidence and sustainable waste disposal solutions.

“As global energy demand accelerates, nuclear power has an increasingly important role to play in delivering reliable, low-carbon electricity,” said Baltzer. “But responsible nuclear growth requires us to think beyond electricity generation and address the entire nuclear lifecycle, including permanent waste disposal. We are excited to join Economist Enterprise and fellow industry leaders to explore how innovation, investment and community collaboration can help build a sustainable nuclear future.”

Deep Isolation is advancing deep borehole disposal technology designed to provide a safe, scalable and potentially cost-effective pathway for the permanent isolation of spent nuclear fuel and high-level radioactive waste. The Company’s participation in the Economist Enterprise event reflects its commitment to supporting responsible nuclear energy expansion through scientifically grounded waste management solutions.

To register for the free event, visit: https://events.economistenterprise.com/custom-events/the-energy-horizon/

About Deep Isolation

Deep Isolation (OTCQB: DBHL) is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. Deep Isolation’s solution will offer a unique approach to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International (TYO: 7004), and Occlusion Nuclear Solutions.

For more information, visit: https://www.deepisolation.com

Media Contact
Sophie McCallum
media@deepisolation.com

Investor Contact
Caldwell Bailey
InvestorRelations@deepisolation.com

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards and our ability to finalize negotiations on same; our failure to manage our growth effectively or to execute our business plan; our failure to sustain and expand relationships with governmental entities and strategic partners; a failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law.

Additional information concerning the factors above and other factors will be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Reports on Form 10-K and 10-Q for the fiscal year ended December 31, 2025 and the quarter ending March 31, 2026, respectively, as filed with the SEC on March 30, 2026, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation at InvestorRelations@deepisolation.com or CorpSec@deepisolation.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/37c5d20c-49c5-4ee4-9c45-75035810867a

PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 2, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/54689.

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more of follow us on LinkedIn and X.

CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com

• Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel
• One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that the Company will present eight abstracts, including one oral presentation, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from October 21-25, 2026, in Denver, CO.

“The data being presented at Kidney Week 2026 continue to build a more cohesive picture of how rilparencel may lead to stabilization of kidney function,” said Bruce Culleton, M.D., CEO of ProKidney. “Across multiple complementary non-clinical models, we are seeing evidence supporting an adaptive, multifactorial mechanism that involves attenuation of oxidative damage, metabolic dysregulation, and pro-inflammatory signaling, while supporting vascular and tubular repair within diseased and injured kidney cells. Importantly, these mechanistic observations coupled with the stabilization of kidney function observed across our recent Phase 2 studies in patients with advanced CKD and type 2 diabetes further strengthen our confidence in the ongoing Phase 3 PROACT 1 study.”

The titles for the accepted abstracts are provided below and are accessible online at: https://www.asn-online.org/education/kidneyweek/2026/program-search-abstract.aspx

Oral Presentation Details

Rilparencel Is Associated with a Graft-Adjacent Remodeling Response and Preserved Vascular Integrity in an Immunocompromised Rat CKD Model
Abstract Number: FR-OR044
Session Title: Exciting Developments in CKD Research: From Diagnostics to Management and More
Date, Time: October 23, 2026 from 4:30 PM to 6:00 PM MDT (ProKidney presentation starts at 5:40 PM)
Location: Mile High Ballroom 1D

Poster Presentation Details

A Human Microphysiological System Resolves Epithelial Inflammatory Injury Programs and Characterizes Autologous Cell Therapy Responses in a CKD Injury Model
Session Title: Bioengineering: Emerging Research
Date, Time: October 22, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: TH-PO1128

Long-Duration Air-Liquid Interface Culture of Human CKD Kidney Biopsies Enables Ex Vivo Study of Disease Biology and Tissue-Context-Specific Effects of Kidney-Targeted Therapies
Session Title: Bioengineering: Emerging Research
Date, Time: October 22, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: TH-PO1129

Metabolic Transitioning During Manufacturing of Renal Cell Therapy Candidate Rilparencel
Session Title: CKD: Mechanisms of Injury and Fibrosis – 2
Date, Time: October 23, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: FR-PO0236

Renal Autologous Cell Therapy for CKD with Diabetes: Pooled Safety and Efficacy Results from a Phase 2 Program in a Subset of Participants with Key Phase 3 Eligibility Characteristics
Session Title: CKM: Clinical – Trials, Epidemiology, and Biomarkers
Date, Time: October 23, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: FR-PO0498

GPX4-Associated Cytoprotective Activity of an Autologous Cell Therapy in Human In Vitro and Ex Vivo CKD Models
Session Title: Development, Stem Cells, and Regenerative Medicine
Date, Time: October 24, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: SA-PO0013

Rilparencel Manufacturing Induces Transcriptional Dedifferentiation Leading to Two Distinct Populations with Retained Tubular Lineage Memory
Session Title: Development, Stem Cells, and Regenerative Medicine
Date, Time: October 24, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: SA-PO0014

Longitudinal Secretome Characterization of Renal Cell Therapy Candidate Rilparencel During Manufacturing
Session Title: Development, Stem Cells, and Regenerative Medicine
Date, Time: October 24, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: SA-PO0015

Following the event, a copy of the poster presentations will be available on the Company’s website at: https://prokidney.com/our-technology/publications/

About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead investigational product candidate, rilparencel (also known as REACT^®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the achievement and timing of the topline data readout of the Company’s PROACT 1 trial and other milestones provided, the Company’s beliefs that its Phase 3 REGEN-006 (PROACT 1) trial could be sufficient to support a potential BLA submission and full regulatory approval, that eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel, expectations with respect to financial results and expected cash runway, including the Company’s expectation that current cash will support operating plans into mid-2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s products, if approved, the advancement of the Company’s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the Company’s product candidates, and the advancement and funding of the Company’s developmental programs, generally. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company’s Class A common stock on Nasdaq; the inability of the Company’s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company’s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company’s drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company’s business; and other risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

ProKidney Contact
Ethan Holdaway
Ethan.Holdaway@prokidney.com

Media Contact
Audra Friis
audrafriis@sambrown.com

Investor Relations Contact
Daniel Ferry
Daniel@lifesciadvisors.com

– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million –

– Capital now available to support continued growth of the YCANTH® business and advancement of the Company’s global Phase 3 common warts program through topline data readouts, the first of which is expected in Q1’27 –

WEST CHESTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it has achieved the pre-defined revenue, growth and operational milestones required to increase the maximum commitment amount under its credit facility with an entity controlled by Paul B. Manning, Chairman and Chief Executive Officer of PBM Capital and Chairman of Verrica’s Board of Directors. As a result of the achievement of these milestones, the full $27.5 million of non-dilutive capital under the facility is now available to Verrica, with the first $12.5 million having been funded in September.

“Verrica’s achievement of these milestones resulted directly from the momentum our team has built with YCANTH,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “We committed to clear revenue, growth and operational goals when we closed this facility in August, and we delivered on them. Importantly, the capital now available to Verrica by this facility allows us to complete our two pivotal studies in the common warts program, with readouts from the studies expected in the first quarter and in mid-2027, respectively. Under the facility, we have no obligation to make scheduled principal or interest cash payments during the term of the facility, and the favorable covenant package allows us to fully utilize our cash to support our growth. On behalf of all of us at Verrica, I would like to again thank Paul Manning for his confidence in our progress and for providing this highly flexible funding to support our programs.”

“Verrica’s execution over the past several months reinforces my confidence in the team and in YCANTH,” said Paul B. Manning, Chairman of Verrica’s Board of Directors. “I am pleased to continue supporting the Company as it builds on this progress.”

Terms of the Credit Agreement

Under the terms of credit agreement, Verrica may borrow up to $27.5 million from time to time, at its option. Borrowings under the facility will bear interest at the one-month secured overnight financing rate (SOFR) plus 8.00% per annum, subject to a SOFR floor of 4.50%. All interest under the facility will be payable in kind, subject to the absence of any event of default under the credit agreement (which results in interest being payable in cash and increased during the pendency of such event of default, unless otherwise elected by the lender). The term loans will mature on December 31, 2030. The credit agreement also requires mandatory prepayments with the proceeds of certain transactions and events, and quarterly payments if positive operating cash flow exceeds a specified amount. The credit facility is secured by substantially all of the assets of Verrica and certain subsidiaries.

About YCANTH® (VP-102) 

YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum.

Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay as little as $0 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information.

YCANTH is also approved for the treatment of molluscum contagiosum in Japan and is being studied in a global phase 3 program in the US and Japan for the treatment of common warts.

About Verrica Pharmaceuticals Inc. 

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH^® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH^® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about Verrica’s ability to borrow funds under the credit facility, the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315, the timing of readouts from the Phase 3 common warts program and Verrica’s cash runway. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — GPGI, Inc. (NYSE: GPGI), a diversified multi-industry platform for companies with great positions in good industries, today announced it will host a conference call on Thursday, November 5, 2026, at 8:00 a.m. Eastern Standard Time (EST) to discuss its financial results for the third quarter ended September 30, 2026. GPGI’s earnings results will be reported in a press release prior to the call.

GPGI’s leadership team will host the conference call, followed by a question-and-answer session.

Date: Thursday, November 5, 2026
Time: 8:00 a.m. EST
Live webcast registration link: here

We encourage all participants to register at least 15 minutes prior to the 8:00 a.m. EST start time. A live webcast and replay will be available on GPGI’s website at https://gpgi.com/events-presentations/. If you have any difficulty registering for the conference call, please contact GPGI at ir@gpgi.com.

About GPGI

GPGI, Inc. (NYSE: GPGI) is a diversified, multi-industry platform for companies with great positions in good industries. The platform is managed by Resolute Holdings Management, Inc. (NYSE: RHLD) and is purpose-built to acquire, own, and scale high-quality businesses led by great operators, benefiting from a permanent capital base and the systematic deployment of the Resolute Operating System. GPGI currently consists of CompoSecure and Husky – two market leaders with best-in-class financials and durable opportunities for growth. For more information, please visit GPGI.com.

GPGI Contact
ir@gpgi.com